Tan Shing Cheng, Poh Wen Tsin, Yong Audrey Chee Hui, Chua Eng Wee, Ooi Der Jiun, Mahmud Rozi, Thiagarajan Muthukkumaran, Stanslas Johnson
UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Pharmacotherapeutic Unit, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.
Cancer Manag Res. 2023 Aug 21;15:851-862. doi: 10.2147/CMAR.S420890. eCollection 2023.
Considerable progress has been made in cancer drug development in recent decades. However, for people in low- and middle-income countries, including Malaysia, many of these drugs are not readily available. During the 2nd Malaysian Association for Cancer Research (MACR) International Scientific Conference, a forum discussion was held to address these challenges and explore strategies to improve access to cancer medicines in the country. This paper presents the results of the said forum discussion. A few challenges to cancer drug access were highlighted, including lengthy approval and regulatory practices, cost of medicines, and manufacturing barriers. Besides, a few strategies for mitigating some of these challenges were proposed, such as mechanisms for cost reduction, uptake of biosimilars and generics, local manufacturing, public-private partnerships, strengthening the role of insurance companies, funding and regulation, and advocacy for fair pricing, by drawing examples from cancer medicines access initiatives in Malaysia and initiatives for different disease groups. Overall, this paper provides a comprehensive overview of the challenges and strategies for improving access to cancer medicines in Malaysia and provides valuable insights for policymakers, healthcare providers, the pharmaceutical industry, cancer patients, cancer support groups, and other stakeholders working on this important issue.
近几十年来,癌症药物研发取得了长足进展。然而,对于包括马来西亚在内的低收入和中等收入国家的人们来说,许多此类药物难以获取。在第二届马来西亚癌症研究协会(MACR)国际科学会议期间,举行了一场论坛讨论,以应对这些挑战,并探索改善该国癌症药物可及性的策略。本文介绍了上述论坛讨论的结果。会上强调了癌症药物可及性面临的一些挑战,包括冗长的审批和监管程序、药品成本以及生产障碍。此外,还提出了一些应对其中一些挑战的策略,例如成本降低机制、生物类似药和仿制药的采用、本地生产、公私伙伴关系、加强保险公司的作用、资金与监管,以及通过列举马来西亚癌症药物可及性举措和针对不同疾病群体的举措来倡导公平定价。总体而言,本文全面概述了马来西亚改善癌症药物可及性的挑战与策略,并为政策制定者、医疗服务提供者、制药行业、癌症患者、癌症支持团体以及致力于这一重要问题的其他利益相关者提供了宝贵见解。